(3R,5R)-7-bromo-3-ethyl-4-hydroxy-8-methoxy-5-phenyl-3-propyl-2,5-dihydro-1lambda6,4-benzothiazepine 1,1-dioxide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并硫氮卓类
• 英文名称: (3R,5R)-7-bromo-3-ethyl-4-hydroxy-8-methoxy-5-phenyl-3-propyl-2,5-dihydro-1lambda6,4-benzothiazepine 1,1-dioxide
• 英文别名: (3R,5R)-7-bromo-3-ethyl-4-hydroxy-8-methoxy-5-phenyl-3-propyl-2,5-dihydro-1λ6,4-benzothiazepine 1,1-dioxide
• 化学式: C₂₁H₂₆BrNO₄S
• 分子量: 468.4
• InChiKey: XZPQPZFXBVBXIJ-NHCUHLMSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  28
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  75.2
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• [EN] BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF BARRETT'S ESOPHAGUS AND GASTROESOPHAGEAL REFLUX DISEASE<br/>[FR] INHIBITEURS DE RECYCLAGE D'ACIDE BILIAIRE POUR LE TRAITEMENT DE L'ŒSOPHAGE DE BARRETT ET DU REFLUX GASTROŒSOPHAGIEN PATHOLOGIQUE
  申请人：LUMENA PHARMACEUTICALS INC

  公开号：WO2014144485A9

  公开（公告）日：2015-01-15
• BILE ACID RECYCLING INHIBITORS AND SATIOGENS FOR TREATMENT OF DIABETES, OBESITY, AND INFLAMMATORY GASTROINTESTINAL CONDITIONS
  申请人：Satiogen Pharmaceuticals, Inc.

  公开号：EP2575821B1

  公开（公告）日：2015-08-12
• EP2995317A1
  申请人：——

  公开号：EP2995317A1

  公开（公告）日：2016-03-16
• [EN] BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PRIMARY SCLEROSING CHOLANGITIS AND INFLAMMATORY BOWEL DISEASE<br/>[FR] INHIBITEURS DU RECYCLAGE DE L'ACIDE BILIAIRE POUR LE TRAITEMENT DE L'ANGIOCHOLITE SCLÉROSANTE PRIMAIRE ET DE LA MALADIE INFLAMMATOIRE DE L'INTESTIN
  申请人：LUMENA PHARMACEUTICALS INC

  公开号：WO2014144650A2

  公开（公告）日：2014-09-18

  Provided herein are methods of treating or ameliorating primary sclerosing cholangitis and inflammatory bowel disease by administering to an individual in need thereof a therapeutically effective amount of an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating primary sclerosing cholangitis comprising administering to an individual in need thereof a therapeutically effective amount of ASBTI or a pharmaceutically acceptable salt thereof.